PRPhilippe Rauch

Philippe Rauch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Philippe Rauch has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Pre-Therapeutic Assessment in Endometrial Cancer Staging

    by Caroline Bouche, Manuel Gomes David, Julia Salleron, Philippe Rauch, Léa Leufflen, Julie Buhler, Frédéric Marchal

    Objective: The aim of this retrospective cohort study is to evaluate the concordance between the preoperative MRI and histology data with the final histopathological examination. Method: This is a retrospective observational study of 183 patients operated for endometrioid cancer between January 2009 and December 2019 in the surgical oncology department of the Lorraine Cancer Institute (ICL) in Vandœuvre-lès-Nancy. The patients included are all women operated on for endometrioid-type endometrial cancer over this period. The exclusion criteria are patients for whom the pre-therapy check-up does not include pelvic MRI and those who have not had first-line surgery. The final anatomopathological results were compared with preoperative imaging data and with endometrial biopsy data. Results: For the myometrial infiltration, the sensitivity of MRI was of 37% and the specificity of 54%. To detect nodal metastases, the sensitivity of MRI was of 21% and the specificity of 93%. We observed an under estimation of the FIGO classification (p = 0.001) with the MRI in 42.7% of cases (n = 76) and an overestimation in 24.2% of cases (n = 43). There was a concordance in 33.1% of cases (n = 59). We had a poor agreement between the MRI and final histopathological examination with an adjusted kappa (κ) of 0.12 [95% IC (0.02; 0.24)]. There was a moderate concordance on the grade between the pretherapeutic biopsy and the final histopathological examination on excised tissue with an adjusted kappa of 0.52 [95% IC 0.42–0.62)]. Endometrial biopsy underestimated the tumor grade in 28.9% of cases (n = 50) (p < 0.001), overestimated the tumor grade in 6.9% of cases (n = 12) and we observed a concordance in 64.2% of cases (n = 111). Conclusion: The pre-operative assessment of endometrial cancer is inconsistent with the results obtained on final histopathological examination. A study with a systematic review should be done to assess the performance of MRI, only in expert centers, in order to consider a a specific care management for endometrial cancer patients: patients who have had an MRI in an outpatient center should have their imaging systematically reviewed, with the possibility of a new examination in case of incomplete sequences, by expert radiologists, and discussed in multidisciplinary concertation meeting in expert centers, before any therapeutic decision. The sentinel node biopsy must be used for low and intermediate risk endometrial cancer.


  • Limited effectiveness of patent blue dye in addition to isotope scanning for identification of sentinel lymph nodes: Cross-sectional real-life study in 1024 breast cancer patients

    by Philippe Rauch, Jean-Louis Merlin, Lea Leufflen, Julia Salleron, Alexandre Harlé, Pierre Olivier, Frédéric Marchal

    Although morbidity is reduced when sentinel lymph node (SLN) biopsy is performed with dual isotopic and blue dye identification, the effectiveness of adding blue dye to radioisotope remains debated because side effects including anaphylactic reactions. Using data from a prospectively maintained database, 1884 lymph node-negative breast cancer patients who underwent partial mastectomy with SLN mapping by a dual-tracer using patent blue dye (PBD) and radioisotope were retrospectively studied between January 2000 and July 2013. Patients with tumors 1 node detected by one of the two techniques (N = 1024) were included in this real-life cross-sectional study. Among the 1024 patients, 274 had positive SLN detected by isotopic and/or PBD staining. Only 4 patients having no detectable radioactivity in the axilla had SLN identified only by PBD staining (blue-only) while 26 patients had SLN only identified by isotopic detection (hot-only) illustrating failure rates of 9.5% (26/274) and 1.5% (4/274), respectively. Among these four patients, two had negative lymphoscintigraphy. Therefore, the contribution of PBD to metastatic nodes identification was relevant for only 2/274 patients (0.8%). Three patients (0.3%) had an allergic reaction with PBD, and anaphylactic shock occurred in two cases (0.2%). The added-value of PBD to reduce the false-negative rate of SLN mapping is only limited to the rare cases in which no radioactivity is detectable in the axilla (<1%). When a radioisotope mapping agent is available, the use of PBD should be avoided, because it can induce anaphylaxis.


  • Treatment of Vulvar Intraepithelial Neoplasia With CO2 Laser Vaporization and Excision Surgery

    by Léa Leufflen, Pauline Jr Baermann, Philippe Rauch, Thierry Routiot, Lina Bezdetnava, Francois Guillemin, Emmanuel Desandes, Frederic Marchal

    Objective To evaluate the recurrence rate after a single treatment of vulvar intraepithelial neoplasia (VIN) with CO2 laser vaporization. Materials and Methods Fifty women with usual-type or differentiated VIN (grades 2 and 3) treated with CO2 laser vaporization or surgery excision (cold knife or CO2 laser) were retrospectively evaluated. Results Of the 50 patients, 41 (82.0%) had usual-type VIN and 9 (18.0%) had differentiated VIN. Moreover, 24 (48.0%) were treated with surgery excision and 26 (52.0%) underwent CO2 laser vaporization. Laser-treated patients were significantly younger (p < .01) with more multifocal (p < .05) and multicentric lesions (p < .01) than in the surgery group. Recurrence-free survival (RFS) rates at 1 year were 91.0% for the surgery and 65.2% for the laser vaporization groups (p < .01). At 5 years, RFS rates were unchanged for the surgery group and dropped to 51.3% (p < .01) for the laser group. On the univariate analysis, current smoker (p = .03), multicentric VIN (p = .02), and laser vaporization treatment (p < .01) had a statistically significant impact on RFS. One patient progressed to invasive cancer (2%). Conclusions The recurrence rate after CO2 laser vaporization requires regular, close, and extended monitoring.


  • Open Access

    Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

    by Lionel Uwer, Christine Rotonda, Francis Guillemin, Joëlle Miny, Marie-Christine Kaminsky, Mariette Mercier, Laetitia Tournier-Rangeard, Isabelle Leonard, Philippe Montcuquet, Philippe Rauch, et al.

    Background: The aim of this study was to compare the responsiveness of the European Organization for Research and Treatment (EORTC) quality of life questionnaires (QLQ-C30, QLQ-CR38) and the Functional Assessment of Cancer Therapy-colorectal version 4 questionnaire (FACT-C). Method: This prospective study included 127 patients with colorectal cancer: 71 undergoing chemotherapy and 56 radiation therapy. Responsiveness statistics included the Standardized Response Mean (SRM) and the Effect Size (ES). The patient's overall assessment of his/her change in state of health status was the reference criterion to evaluate the responsiveness of the QoL questionnaires. Results: 34 patients perceived their health as stable and 17 as improved between the first and the fourth courses of chemotherapy. 21 patients perceived their health as stable and 22 as improved between before and the last week of radiotherapy. The responsiveness of the 3 questionnaires differed according to treatments. The EORTC QLQ-C30 questionnaire was more responsive in patients receiving chemotherapy, particulary functional scales (SRM > 0.55). The QLQ-CR38 and the FACT-C questionnaires provided little clinically relevant information during chemotherapy or radiotherapy. Conclusion: The EORTC QLQ-C30 questionnaire appears to be more responsive in patients receiving chemotherapy.


  • Cœlioscopie et télérobotique

    by F Marchal, Philippe Rauch, Jeanluc Verhaeghe, Francois Guillemin

    • 24 September 2004
      • Vol. 91, 621-8

    [Use of sentinel lymph node technique in cutaneous melanoma: preliminary experience].

    by Frédéric Marchal, Philippe Rauch, Pierre Olivier, Agnès Leroux, Lionel Geoffrois, Gilles Dolivet, Jean-Luc Verhaeghe, François Guillemin

    The aim of this study was to determine the contribution of the technique of sentinel lymph node (SLN) biopsy by preoperative lymphoscintigraphy and patent blue injection in management of primary cutaneous melanoma (MM). Sixty three patients with stade I primary MM were operated between March 1999 and January 2003. Preoperative lymphoscintigraphy was performed the day before surgery and peroperative patent blue injection was used to identify SLN. All hot and/or blue lymph nodes were removed and examinated in standard histology and immunohistochemistry. The population was 31 men and 32 women. The MM were distributed between upper extremities (9), lower extremities (24), trunk (19) and head and neck (11). A SLN was identified in 98%. Aberrant drainages were found in 13%. The average number of SLNs removed was 3.6 [0-15]. Fourteen patients (22%) had SLN positive for malignant disease, with micrometastasis in nine cases. The sentinel node was false-negative in 12.5% with a medial follow-up of 14 months. In conclusion, preoperative lymphatic mapping combined used of peroperative detection by a hand-held gamma probe and patent blue injection is a feasible technique to specify the first drainage of MM.